Global medicine-source catalogue

Atorvastatin, rosuvastatin, pravastatin, fluvastatin, lovastatin, simvastatin and pitavastatin are not one medicine that can be self-converted from milligram numbers. Do not alternate them by day, rotate products or combine them yourself. MEVALOTIN is the Japanese pravastatin sodium dossier: 5/10 mg tablets state the amount per tablet, while 0.5%/1% fine granules state 5/10 mg per 1 g. Tablets and granules, and pravastatin and other statins, must not be rotated or converted from numbers alone. LESCOL XL is a fluvastatin sodium 80 mg extended-release tablet. Conventional LESCOL 20/40 mg capsules are a different dosage form and must not be converted, assembled or substituted from total milligrams alone; swallow the extended-release tablet whole without breaking, crushing or chewing it. MEVACOR is the historical 1987 originator-brand lovastatin archive, and FDA currently lists its 10/20/40 mg rows as DISCN. A current exact 40 mg generic pack is shown separately and is not presented as the historical brand. Conventional lovastatin must not be numerically conflated with ALTOPREV extended-release tablets, the ADVICOR combination or another statin; clarithromycin and other strong CYP3A inhibitors are priority interaction-review scenarios. One VYTORIN tablet already contains both ezetimibe and simvastatin and must not be self-assembled by brand name with ZETIA, ZOCOR or another statin. Its four label strengths, eight bottle NDCs and the RS status of 10/80 mg are product and regulatory identities, not advice to choose or increase an individual's strength. TRICOR is fenofibrate, not a statin. Its historical 48 mg and 145 mg RLD strengths are not an arithmetic invitation to replace 145 mg with three 48 mg tablets. FDA currently lists both brand rows as DISCN. The dated label says to swallow the tablets whole and not to crush, break, dissolve or chew, and prioritises myopathy review with a statin or colchicine, older age or renal impairment. This site does not choose a medicine for an individual from genes, laboratory results or symptoms.

MONOPRIL is the historical U.S. originator/RLD for fosinopril sodium immediate-release tablets. Its historical 10/20/40 mg entries are currently DISCN and not withdrawn for safety or effectiveness; the current public reading source is a generic fosinopril label, not a MONOPRIL pack. The per-tablet milligram figures do not establish an individual tablet count or conversion to MONOPRIL-HCT, another ACE inhibitor or an ARB. Older adults and people with several medicines require priority review of potassium, kidney function, low blood pressure and falls when a diuretic, potassium supplement or salt substitute, NSAID, lithium or another renin-angiotensin-system medicine is on the list. CATAPRES is the historical U.S. originator/RLD for clonidine hydrochloride immediate-release tablets. The historical 0.1/0.2/0.3 mg strengths are DISCN and not withdrawn for safety or effectiveness. Exact images come only from the current generic under ANDA 070923 and are not original-brand packs. The 0.05/0.1/0.2/0.3 mg figures are amounts per tablet and 100/500/1000 Tablets are bottle counts; a score does not automatically permit splitting or tapering. Older adults and people with several medicines require priority review of somnolence, dry mouth, orthostatic hypotension, bradycardia, falls, and rebound hypertension, headache, nervousness/agitation and tremor after abrupt withdrawal. Co-listing a beta blocker especially must not lead to self-selecting which medicine to stop first. CATAPRES-TTS patch, DURACLON injection, KAPVAY/JENLOGA/NEXICLON XR extended-release products, JAVADIN oral solution and COMBIPRES combination cannot be self-converted, assembled or substituted from shared clonidine or milligram figures. APRESOLINE is the historical U.S. originator/RLD for hydralazine hydrochloride immediate-release tablets. All four historical oral strengths are currently DISCN and not withdrawn for safety or effectiveness. Exact images on the page come only from the current generic under ANDA 200770 and are not original-brand packs. The 10/25/50/100 mg figures are amounts per tablet and 100/500/1000 Tablets are bottle counts. The current tablets are unscored, and arithmetic does not permit self-splitting. Older adults and people with several medicines require priority review of orthostatic hypotension, syncope/falls, tachycardia and angina/chest pain, lupus-like reactions, glomerulonephritis, peripheral-neurological symptoms, complete blood count and antinuclear-antibody monitoring boundaries. APRESOLINE injection, the BIDIL isosorbide dinitrate/hydralazine combination, ISORDIL and other antihypertensives cannot be self-assembled, converted or substituted from a shared purpose, ingredient or milligrams. HYGROTON is the historical originator/RLD for chlorthalidone. It is discontinued, and FDA review states that withdrawal was not for safety or efficacy reasons. Exact images on this page are current Mylan/Viatris generic labels and must never be read as original HYGROTON appearance. The 25/50 mg figures are per-tablet amounts and 100/1000 Tablets are bottle counts; a score on 50 mg does not automatically permit halving. Older adults, people with many medicines, vomiting/diarrhoea or reduced food/fluid intake require priority review of dehydration, orthostatic hypotension, falls, sodium/potassium/magnesium, kidney function, uric acid/gout, glucose, digoxin, lithium, NSAIDs, other diuretics and blood-pressure medicines. Chlorthalidone, hydrochlorothiazide, indapamide, furosemide and potassium-sparing diuretics cannot be self-converted, alternated or combined from a shared diuretic purpose or milligrams. CARDURA is immediate-release doxazosin. The 1/2/4/8 mg figures are amounts per tablet and 100 Tablets is the bottle count. CARDURA XL is a separate 4/8 mg product with a different NDA and extended-release structure, so a shared ingredient and number do not permit one-for-one substitution. Co-listing CARDURA with FLOMAX, another alpha blocker, a PDE-5 inhibitor such as CIALIS/VIAGRA or another blood-pressure medicine requires priority review of orthostatic hypotension, syncope and falls. Tell the eye team before cataract surgery and do not self-stop. ATACAND is a single-ingredient candesartan cilexetil oral tablet; 4/8/16/32 mg are amounts per tablet. ATACAND HCT/PLUS additionally contains hydrochlorothiazide and must not be self-combined or substituted from a shared brand stem. ATACAND and other ARBs such as COZAAR, DIOVAN, BENICAR, AVAPRO or MICARDIS likewise cannot be converted one-to-one by milligrams, alternated or combined. Co-listing potassium supplements or salt substitutes, an NSAID pain medicine, lithium or another renin-angiotensin-system medicine requires priority review of kidney function, potassium and the complete medicine list. LOZOL is the historical U.S. originator/RLD for immediate-release indapamide. The 1.25/2.5 mg strengths are discontinued and not withdrawn for safety or effectiveness. Exact images come only from the current ANI generic and are not original-brand packs. Older adults, especially older women, require priority review of hyponatraemia with hypokalaemia, dehydration, orthostatic hypotension and falls, as well as lithium, digoxin/cardiac glycosides, corticosteroids, other diuretics and antihypertensives. Immediate- and modified-release products, and indapamide versus chlorthalidone, hydrochlorothiazide or furosemide, cannot be self-converted, alternated or combined from shared purpose or milligrams. One DIOVAN HCT tablet contains valsartan and hydrochlorothiazide and must not be confused with single-ingredient DIOVAN or MICROZIDE, or with shared-ingredient products such as EXFORGE HCT, HYZAAR or AVALIDE. One ZESTORETIC tablet contains lisinopril and hydrochlorothiazide and must not be confused with single-ingredient ZESTRIL, MICROZIDE or another hydrochlorothiazide combination. One LOTREL capsule contains amlodipine and benazepril and must not be confused with NORVASC, LOTENSIN or another ACE inhibitor such as ZESTRIL, VASOTEC, ALTACE or CAPOTEN; ENTRESTO also has a special label boundary with ACE inhibitors. LOTENSIN is single-ingredient immediate-release benazepril; the current U.S. label lists 10, 20 and 40 mg in three 100-tablet bottles, while historical 5 mg is not rewritten as a current pack. LOTENSIN HCT and LOTREL are separate combination products. Switching with ENTRESTO has a 36-hour boundary, while potassium, potassium salt substitutes, NSAIDs, lithium, another ACE inhibitor/ARB, hypotension, kidney function and fall risk require priority review rather than self-stopping or switching. Australian COVERSYL arginine 2.5/5/10 mg and Canadian erbumine 2/4/8 mg are not a web conversion table. COVERSYL PLUS and COVERAM contain additional ingredients and must not be self-combined, stopped or switched with single-ingredient or another ACE inhibitor. FDA currently lists all six historical LOTREL RLD strengths as Discontinued; a public label is a reading archive, not evidence of current supply. One AZOR tablet contains amlodipine and olmesartan medoxomil and must not be confused with single-ingredient NORVASC or BENICAR, or with shared-ingredient products such as LOTREL, EXFORGE, CADUET, BENICAR HCT or TRIBENZOR. All four strengths are currently listed as prescription RLD products, and 10/40 mg is also the RS. One CADUET tablet contains amlodipine and atorvastatin and must not be self-combined with single-ingredient NORVASC or LIPITOR, or with LOTREL, AZOR, EXFORGE, EXFORGE HCT or TRIBENZOR, which share amlodipine. The current DailyMed label displays eight packs while the Orange Book lists 11 prescription RLD strengths and identifies 10/80 mg as RS; these records must not be rewritten as real-time supply. One TRIBENZOR tablet further contains olmesartan medoxomil, amlodipine and hydrochlorothiazide; all five strengths are currently prescription RLD products and 40/10/25 mg is also the RS. It must not be self-combined with AZOR, BENICAR, NORVASC, MICROZIDE or another shared-ingredient combination. One HYZAAR tablet contains losartan and hydrochlorothiazide. Seeing these products together may indicate ingredient duplication; do not add, stop or arrange a switch yourself when duplication is suspected. KLOR-CON 8 mEq (600 mg) and 10 mEq (750 mg) state the electrolyte equivalent and potassium chloride mass together; do not add the numbers or treat mEq as a tablet count. Seeing it with an ACE inhibitor, ARB, spironolactone, NSAID or potassium-sparing diuretic requires potassium and kidney review, not automatic supplementation. TOPROL-XL is extended-release metoprolol succinate, while LOPRESSOR is a regular metoprolol tartrate tablet. Long-acting products such as PROCARDIA XL likewise cannot be interchanged with regular tablets from a generic name or milligram number alone. BYSTOLIC is nebivolol, not metoprolol, bisoprolol, atenolol, propranolol or carvedilol. Do not self-convert milligrams, alternate it, add another beta blocker or abruptly stop it. Low pulse, dizziness/fainting, diabetes, or co-listing with digoxin, diltiazem/verapamil, clonidine, fluoxetine or paroxetine requires priority review. COREG is an immediate-release carvedilol tablet, while COREG CR is a carvedilol phosphate extended-release capsule. Even though the label contains professional conversion information, a shared brand stem, milligram figures or frequency must not be used for self-conversion. Take CR with food and do not crush or chew it; if opened as the label allows, all beads must be sprinkled on applesauce that is not warm and consumed immediately in full. Have a pharmacist or clinician review the front and back of every pack, the full medicine list and the prescription together.

BETAPACE and BETAPACE AF both contain sotalol hydrochloride but correspond to NDA 019865 and NDA 021151 respectively; a shared ingredient or milligram figure does not permit self-interchange. They carry a boxed warning for life-threatening proarrhythmia, so QT, heart rate, kidney function, potassium and magnesium, and the complete medicine list require joint review. If amiodarone, digoxin, verapamil/diltiazem, another beta blocker, clonidine, a diuretic or another QT-prolonging medicine appears on the same list, do not self-combine, separate, alternate, stop or make up a dose. Check the dosage form, strength, schedule and full medicine list for every pack in this group. Do not increase, stop, alternate or make up a dose because of a heart-rate, chest-symptom or blood-pressure number. RANEXA is a prolonged-release tablet swallowed whole for chronic stable angina, not an acute-rescue substitute for sublingual nitroglycerin. IMDUR is a preventive isosorbide mononitrate extended-release medicine, while ISORDIL is an immediate-release oral isosorbide dinitrate preventive tablet. Neither is acute chest-pain rescue, and neither can be converted or substituted by milligram figures with MONOKET immediate-release tablets or nitroglycerin products such as NITROSTAT. ISORDIL also had sublingual and extended-release products historically; a shared brand stem does not merge them. The exact UK Imdur 60 mg product is described as divisible but must not be chewed or crushed. U.S. labelled ISORDIL 5/40 mg tablets are deeply scored, but the site does not treat that as permission to self-split. PDE-5 inhibitors and riociguat with organic nitrates are priority contraindication reviews, not situations for inventing separation intervals. CALAN is the historical originator/RLD for immediate-release verapamil tablets. The current generic 40/80/120 mg packs displayed here cannot be interchanged by generic name or milligrams with extended-release or chronotherapeutic products such as CALAN SR, VERELAN or VERELAN PM. If verapamil appears with CARDIZEM LA, a beta blocker, digoxin, clonidine or amiodarone, prioritise review of heart rate, conduction, pressure and cardiac function.

One AGGRENOX capsule already contains an immediate-release aspirin 25 mg tablet and extended-release dipyridamole 200 mg pellets. The numbers belong to two ingredients, not one 225 mg medicine, and the capsule must not be opened, crushed, divided into pellets or self-assembled from individual components. Another aspirin, clopidogrel, ticagrelor, prasugrel, cilostazol, anticoagulant, heparin, fibrinolytic, anagrelide or chronically used NSAID on the list requires priority review of ingredient duplication and bleeding risk. Timing separation, symptoms or a shared antithrombotic purpose does not permit self-combination, rotation, stopping or substitution. One DuoPlavin tablet already contains clopidogrel 75 mg plus aspirin 75 mg or 100 mg. The figures belong to two ingredients, not one 150/175 mg medicine. Another PLAVIX/clopidogrel, aspirin, aspirin-containing pain/cold product, antiplatelet, anticoagulant, heparin, thrombolytic or NSAID requires review for ingredient duplication and bleeding risk. Do not self-combine, separate, stop or substitute when duplication is suspected; tell physicians and dentists before surgery or dental work. This group only helps identify common higher-risk oral medicines and open the matching leaflet. PLETAL / Pletaal is a cilostazol dossier whose current Japanese OD tablets must remain separate from historical U.S. conventional tablets. Heart failure is a priority boundary, and seeing it with aspirin, clopidogrel, another antiplatelet, an anticoagulant or an NSAID pain medicine does not permit self-combination, time-separation or substitution. Do not self-combine, make up a dose, stop, alternate, or add pain medicine based on similar names, pack appearance, milligram numbers, or how you feel; bring the full medicine list and actual packs for item-by-item review by a pharmacist or clinician.

TRADJENTA identifies a U.S. linagliptin single-ingredient tablet record. The current U.S. label lists 5 mg per tablet; that does not create an individual tablet-count, switching or duplicate-use instruction. TRADJENTA, JENTADUETO and JENTADUETO XR require item-by-item checking of ingredients, dosage form, strength and the label for the actual market. If severe or persistent symptoms occur, or insulin, a sulfonylurea or another glucose-lowering medicine is involved, confirm with a clinician or pharmacist first. NovoNorm, PRANDIN and NovoNorm's China-market name identify repaglinide brand records. The 0.5, 1 and 2 mg figures are per-tablet amounts, not an individual meal or tablet count generated by this site. The label links use to main meals, but the site does not generate a meal-time, missed-meal or make-up plan. Hypoglycaemia, the gemfibrozil contraindication, clopidogrel, other glucose-lowering medicines and beta blockers that may mask hypoglycaemia require priority review. PRANDIMET also contains metformin and must not be combined with the single-ingredient product by brand name. ONGLYZA is a single-ingredient saxagliptin tablet. The 2.5 mg and 5 mg figures are per-tablet amounts, and the label says not to split or cut the tablets. KOMBIGLYZE XR, QTERN and QTERNMET XR may share saxagliptin and must not be self-combined by brand name. Pancreatitis, heart failure, kidney function and hypoglycaemia risk with insulin or a sulfonylurea require priority review. JANUMET and JANUMET XR both contain sitagliptin and metformin, but the former is immediate-release and the latter extended-release; a shared brand stem or milligram figures do not permit self-interchange. All three U.S. labelled JANUMET XR strengths are swallowed whole and must not be broken, cut, crushed or chewed. JENTADUETO XR already contains linagliptin and metformin HCl and must not be self-assembled by brand name with TRADJENTA, GLUCOPHAGE, immediate-release JENTADUETO or another shared-ingredient product. Its two milligram figures belong to two ingredients, and both extended-release tablets must be swallowed whole and must not be split, crushed, dissolved or chewed. XIGDUO XR contains dapagliflozin and metformin HCl; and SYNJARDY XR contains empagliflozin and metformin HCl. Do not self-add JANUVIA, FARXIGA, JARDIANCE, GLUCOPHAGE or another shared-ingredient product from brand names alone. XIGDUO XR's two milligram figures belong to two ingredients, and all five extended-release tablets must be swallowed whole, not cut, crushed or chewed. SYNJARDY XR's two milligram figures likewise belong to two ingredients; all four extended-release tablets must be swallowed whole and must not be split, crushed, dissolved or chewed. U.S. SYNJARDY XR extended-release tablets and EU Synjardy immediate-release tablets must not be merged from a shared brand stem. GLUCOTROL XL and DIAMICRON MR are both modified-release products, but their ingredients and release systems differ. GLUCOTROL XL must be swallowed whole, and an empty shell in stool usually does not mean failed absorption. RYBELSUS has specific empty-stomach swallowing instructions, and the current U.S. WEGOVY label lists both oral-tablet and subcutaneous products. A shared class, ingredient, brand or milligram number does not permit self-conversion, co-use or substitution. Check the name, ingredients, route, dosage form, strength and actual pack together. This site does not calculate an individual tablet count or injection amount, or change medicines from a glucose or weight number.

Levothyroxine packs commonly use mcg (micrograms), not mg (milligrams); keep the number, unit, brand and actual pack together. CYTOMEL is T3 liothyronine sodium, and 5, 25 and 50 mcg are micrograms per tablet, not milligrams or an individual tablet count. It cannot be self-converted, combined or alternated numerically with T4 levothyroxine products such as SYNTHROID or EUTHYROX. Older adults and people with cardiovascular disease also need priority review of heart rate, angina and atrial-fibrillation risk. TAPAZOLE is a historical methimazole brand, and 5 mg or 10 mg is an amount per tablet rather than an individual tablet count supplied by the website. Fever, chills, sore throat, repeated infection, jaundice, dark urine or unusual fatigue are important labelled reasons for timely clinical contact, not symptoms to dismiss as a cold or use for self-stopping or switching. An antithyroid medicine and thyroid hormone must not be self-combined, alternated or offset from symptoms or laboratory numbers. Oral osteoporosis medicines may have special frequency, swallowing and posture instructions, so a weekly label or milligram number cannot be used to self-convert, split or make up a dose.

The same symptom may involve very different medicines, and regular tablets, orally disintegrating tablets, extended-release tablets, capsules and oral solutions are not the same product form. NAMZARIC already contains memantine and donepezil, so it must not be self-added to NAMENDA, NAMENDA XR, ARICEPT or another same-ingredient product from brand names alone. EXELON capsules, the 2 mg/mL oral solution and EXELON PATCH use mg per capsule, mg/mL and mg/24h respectively and must not be self-converted, combined or alternated. PROPECIA and PROSCAR both contain finasteride but are separate exact 1 mg and 5 mg products with different labelled uses; PROSCAR 5 mg is not permission to cut five self-made PROPECIA portions. HYTRIN is the historical U.S. originator/RLD for terazosin tablets/capsules; it is discontinued and not for safety or effectiveness reasons. Images on the page are current generic packs and must not impersonate HYTRIN. Starting or restarting terazosin after interruption can cause marked blood-pressure lowering, syncope and falls, so older adults must not self-restart or increase it. RAPAFLO is the historical U.S. originator brand for silodosin 4/8 mg capsules, and FDA currently lists both strengths as DISCN. UROXATRAL is a three-layer 10 mg extended-release tablet that must not be crushed, split or chewed; FLOMAX is a tamsulosin capsule, while CARDURA and CARDURA XL are separate immediate- and extended-release doxazosin products. Similar symptoms or alpha-blocking mechanisms create no milligram conversion, combination, alternation or substitution rule. PROSCAR, PROPECIA, AVODART, HYTRIN, RAPAFLO, UROXATRAL, FLOMAX, MYRBETRIQ, DITROPAN XL, DETROL LA, VESIcare, CIALIS and VIAGRA also have different ingredients and product boundaries; CIALIS and VIAGRA are likewise not one medicine that can be self-converted, combined or substituted from milligram numbers. Bring the actual packs, dosing device, full medicine list and symptom changes for item-by-item review by a pharmacist or clinician.

Capsules, immediate-release tablets, extended-release tablets, suspensions and products from different markets under one generic name cannot be exchanged from milligram numbers alone. SUPRAX 400 mg capsules state the amount per capsule, while the 500 mg/5 mL suspension states concentration after reconstitution; they are not one presentation that can be self-converted or exchanged from the numbers. CEFTIN tablets use mg per tablet while suspension uses mg/5 mL after reconstitution. BIAXIN 500 mg immediate-release and BIAXIN XL 500 mg extended-release tablets are also not one release product, while 125 or 250 mg/5 mL is concentration after constitution. Clarithromycin also has important interaction boundaries. Do not use leftovers, share, alternate products or assemble a course because symptoms seem similar; have the actual pack, prescription, dosing device, allergy history and complete medicine list reviewed item by item by a pharmacist or clinician.

VOLTAREN-XR is the historical U.S. RLD for diclofenac sodium 100 mg extended-release tablets, and the brand record is currently DISCN. The pink ING/278 image on the page comes from a current generic comparator, not the originator-brand package. Diclofenac sodium extended-release tablets, diclofenac sodium delayed-release tablets and diclofenac potassium immediate-release tablets are not necessarily bioequivalent even at the same milligram strength and must not be self-converted, assembled, halved or interchanged. Diclofenac also must not be self-combined with analgesic-dose aspirin, ibuprofen, naproxen, meloxicam, celecoxib, etoricoxib or another NSAID. Older adults and people co-using an anticoagulant/antiplatelet medicine, SSRI/SNRI, ACE inhibitor/ARB, diuretic, lithium, methotrexate or ciclosporin require priority review of gastrointestinal bleeding, cardiovascular, kidney, oedema and full-list risks. NAPROSYN, EC-NAPROSYN, ANAPROX DS and ALEVE may all form the naproxen active moiety and must not be self-combined. NAPROSYN 500 mg is a conventional naproxen tablet, EC-NAPROSYN 375/500 mg is a delayed-release enteric-coated tablet that must not be broken, crushed or chewed, and ANAPROX DS 550 mg is a naproxen sodium tablet; shared names, milligrams or scores do not permit self-interchange. Older adults and people co-using aspirin, anticoagulant/antiplatelet medicines, an SSRI/SNRI, ACE inhibitor/ARB, diuretic, lithium, methotrexate or another NSAID require priority review of gastrointestinal bleeding, cardiovascular, kidney, oedema and full-list risks. CARAFATE tablets contain 1 g per tablet, while the suspension states 1 g per 10 mL. Equivalence between the forms has not been demonstrated, so 10 mL must not be self-exchanged for one tablet. Dysphagia, renal impairment or dialysis, or co-listing with digoxin, a fluoroquinolone, levothyroxine or warfarin requires priority pharmacist review; the site does not generate a personal separation schedule. LIALDA is a 1.2 g mesalamine delayed-release tablet. The 1.2 g figure is per tablet and 120 Tablets is the bottle count. Swallow it whole without splitting or crushing. Its pH-dependent coat begins to break down at about pH 6.8 or above, normally in the terminal ileum, followed by extended release. ASACOL HD, PENTASA, APRISO, DELZICOL and rectal products may share mesalamine but cannot be self-converted or substituted by total milligrams. Older age, changed kidney function, an NSAID, azathioprine or 6-mercaptopurine on the same list requires priority professional review of kidney function, blood counts and platelets. “Common” does not mean safe to add to prescription medicines. Regular strength, maximum strength, combination, tablet and liquid products in one brand family may be different products. ZOFRAN conventional tablets, ZOFRAN ODT and 4 mg/5 mL oral solution must remain separate. Do not push an ODT through the foil; it also carries an aspartame/phenylalanine cue. Another QT-prolonging or serotonergic medicine on the list requires priority review, and apomorphine co-use is a labelled contraindication. Each MiraLAX packet contains 17 g, while the bottle uses its original cap filled to the marked line for 17 g; 17 g equals 17,000 mg as unit conversion only. The marked cap is not an ordinary spoon and does not establish personal use. CREON units are not ordinary milligrams either; pancreatic-enzyme activity units cannot be converted directly to another medicine's mg value. U.S. LINZESS capsules contain 72, 145 or 290 mcg per capsule. The swallowing-difficulty route uses the complete contents of one capsule and does not permit visual halving. Japanese Linzess 0.25 mg is a tablet, and the fact that 0.25 mg equals 250 mcg does not establish cross-market substitution. AMITIZA 8 and 24 mcg are per-softgel strengths of lubiprostone; the softgel must be swallowed whole and not cut open to squeeze out half. Severe diarrhoea, vomiting, dizziness or fainting requires priority review when blood-pressure medicines or other laxatives are on the same list. ADVIL, ALEVE, FELDENE, MOBIC, CELEBREX and ARCOXIA likewise must not be self-combined, alternated or converted merely because all may be used for pain. OXYCONTIN is a higher-risk extended-release opioid tablet that must be swallowed whole and not cut, broken, chewed, crushed or dissolved; alcohol, sleeping sedatives or another CNS depressant on the same list requires priority review for profound sedation and respiratory depression. ULTRAM is a historical tramadol brand whose marketing ended and NDA was withdrawn; the current generic comparator still carries opioid, breathing, seizure, serotonin, alcohol and sedative risks, and a tablet score is not self-halving permission. Have the actual packs, OTC products, supplements and full medicine list reviewed together; the site provides no individual tablet count, millilitres or course.

TESSALON is the historical benzonatate brand record, while current safety reading comes from a 2026 generic label. The 100 mg and 200 mg figures are strengths per capsule. The capsule must be swallowed whole and must not be broken, chewed, dissolved, cut or crushed. Do not wait for symptoms after any child ingestion or suspected overdose; immediately contact local emergency or poison services. Read the active ingredient before relying on a brand or ‘night/cold/allergy’ wording. The BENADRYL label warns of marked drowsiness and against another diphenhydramine product. XYZAL is levocetirizine, and its prescription tablet/oral solution must remain separate from OTC XYZAL ALLERGY 24HR. Age 65 or older, kidney disease, urination difficulty, alcohol or other sedatives, and severe itching after stopping long-term regular use all need priority review. A related mechanism with ZYRTEC/cetirizine or another antihistamine creates no milligram conversion, combination or rotation rule. This MUCINEX dossier is an extended-release tablet whose current label says not to crush, chew or break it. SINGULAIR is a separate prescription product, and its film-coated tablets, chewable tablets and granules are not one pack that can be self-converted. The site identifies the exact product and does not generate an individual tablet count.

ZYLOPRIM, ULORIC and COLCRYS are not one medicine and cannot be self-switched, combined, stopped or made up from joint pain, a urate result or milligram numbers. This COLCRYS dossier uses a dated U.S. historical source. Check each pack's ingredient, dosage form, source date, full medicine list and kidney, liver and interaction information separately. This site does not decide which medicine an individual's current symptoms require.

BARACLUDE, PAXLOVID, VALTREX, ZOVIRAX, MALARONE, KALETRA, XIFAXAN, AVELOX and VFEND differ in purpose, ingredients, dosage forms and interaction boundaries; some dossiers also use dated historical market documents. ZOVIRAX 200 mg capsules, 400/800 mg tablets and 200 mg/5 mL oral suspension also require form-specific checking. A shared connection with infection, travel or antiviral treatment does not permit self-selection, combination, switching or assembly of a course. Do not convert tablet milligrams, oral-liquid mg/mL or intravenous-product numbers across forms. Check the exact pack, purpose, prescription, kidney- and liver-related information, full medicine list and current target-market label item by item.

DELTASONE is the historical U.S. originator/RLD for immediate-release prednisone, and all five historical strengths are currently DISCN. The nine exact package images on the page come from the current generic under ANDA 212629 and are not original DELTASONE packs. The 5/10/20 mg figures are amounts per tablet and 100/500/1000 Tablets are bottle counts; a score does not create permission to split, taper or switch. Immediate-release prednisone, RAYOS delayed-release tablets, prednisolone, MEDROL methylprednisolone and other corticosteroids cannot be self-converted, alternated or combined by milligrams. Older adults and people with several medicines require priority review of infection, glucose, blood pressure/oedema and electrolytes, bone, gastrointestinal bleeding, eye, mood/sleep, muscle weakness and falls. Do not abruptly stop after continuous or longer use or copy an online taper. IMURAN is azathioprine immunosuppression requiring professional management. The 50 mg figure is per tablet and 100 Tablets is the bottle count; a score does not automatically permit splitting. Its boxed malignancy warning, blood counts, serious infection, TPMT/NUDT15, pregnancy, and interactions including allopurinol, febuxostat and co-trimoxazole require priority review. Genetic testing cannot replace CBC monitoring, and the site generates no reduction ratio or separation schedule. MESTINON oral solution, regular tablets and TIMESPAN extended-release tablets cannot be self-converted or substituted from milligram numbers alone. The PLAQUENIL label's 200 mg hydroxychloroquine sulfate and stated equivalent 155 mg hydroxychloroquine are not two medicine amounts. CELLCEPT capsules, tablets, reconstituted suspension and other mycophenolic-acid products likewise cannot be self-interchanged. MEDROL 2, 4, 8, 16 and 32 mg are per-tablet strengths; bottle counts and the 4 mg 21-tablet Dosepak rows are package identity, not a universal schedule. RAYOS is a discontinued U.S. prednisone delayed-release tablet whose intact coating must be preserved; it is not a regular prednisone tablet and cannot be self-converted by milligrams with MEDROL or another corticosteroid. Do not copy rows, split tablets, self-taper, abruptly stop or switch. Have the treating professional review the exact product, monitoring requirements and full medicine list. The site does not generate an individual tablet count, millilitres, interval, taper or stopping plan.

GLEEVEC, TARCEVA, IRESSA, TAGRISSO, ARIMIDEX, FEMARA and NOLVADEX are different products. A cancer name, genetic term, similar purpose or milligram number alone cannot determine individual suitability, co-use or substitution. Some dossiers use dated historical labels, so the target market and source date must be read together. The site only helps identify the exact pack, amount per tablet and official label; it provides no individual course, splitting, stopping, combination or switching plan.

This OFEV dossier covers nintedanib 100 mg and 150 mg oral capsules. The two numbers identify different products; they are not a basis for this site to select, convert or change an amount for an individual. Have the treating professional review the exact pack, prescription, full medicine list, monitoring information and current target-market label.

ELAVIL is the historical U.S. originator/RLD oral-tablet archive for amitriptyline hydrochloride. Its historical 10/25/50/75/100/150 mg entries are all DISCN and not withdrawn for safety or effectiveness; the current public reading source is a generic amitriptyline label, not an ELAVIL pack. The per-tablet mg figures do not establish an individual tablet count or self-conversion, combination or alternation with amitriptyline injection, a chlordiazepoxide combination, another tricyclic antidepressant, an SSRI/SNRI, sedatives or alcohol. Older adults, people with several medicines, glaucoma/urinary or constipation concerns, fall risk or rhythm concerns should have sedation, unsteadiness, anticholinergic effects, rhythm risk and the complete medicine list reviewed by a pharmacist or prescriber. With self-harm/suicide thoughts, fainting, seizure, severe altered awareness, breathing difficulty or inability to remain safe, use local emergency or crisis support immediately; do not wait for a website decision or abruptly self-stop. TOPAMAX is the U.S. brand dossier for topiramate conventional tablets and sprinkle capsules. The 25/50/100/200 mg figures are amounts per tablet, 15/25 mg are amounts per capsule, and 60 Tablets/Capsules is the bottle count. Tablets are swallowed whole and not chewed. Sprinkle capsules may be swallowed whole or opened so all pellets are placed on one teaspoon of soft food, swallowed immediately, not chewed or stored. Older adults and people with several medicines require priority review of thinking/reaction, vision or eye pain, falls, serum bicarbonate, kidney stones, valproate and abrupt withdrawal. A shared antiseizure use, mechanism or milligram figure does not permit self-conversion, combination or rotation with VIMPAT, DEPAKOTE, KEPPRA or another product. VIMPAT is the U.S. brand dossier for lacosamide oral tablets and oral solution. The 50/100/150/200 mg figures are amounts per tablet and 60 Tablets is the carton count; 10 mg/mL is concentration per mL and 200 mL is the bottle volume. Tablets must be swallowed whole and not cut; oral solution requires a medicine measuring device, not a household teaspoon. Older adults and people with several medicines require priority review of dizziness, double vision, gait/falls, cardiac conduction, syncope, liver/kidney function and the complete medicine list. Abrupt stopping may increase seizures. A shared use, sodium-channel mechanism or milligram figure does not permit self-conversion, combination or rotation with KEPPRA, LAMICTAL, TEGRETOL or another product. ATIVAN is the U.S. regulatory dossier for lorazepam C-IV oral tablets. The 0.5/1/2 mg figures are amounts per tablet and 100 Tablets is the bottle count; scores on the 1 mg and 2 mg tablets do not create permission to split. Opioids, alcohol, sleep medicines and other CNS depressants may add respiratory depression and sedation; older adults require priority review of somnolence, unsteadiness and falls. Continued use can produce physical dependence, and abrupt stopping or rapid reduction can be life-threatening. Valproate, probenecid and clozapine also require professional review. A shared class or milligram figure does not permit one-for-one conversion, combination or rotation with VALIUM, XANAX or KLONOPIN. KLONOPIN is the U.S. regulatory dossier for clonazepam C-IV oral tablets. The 0.5/1/2 mg figures are amounts per tablet and 100 Tablets is the bottle count. Only the current 0.5 mg product is listed as scored, which still does not create permission to split or taper. KLONOPIN with VALIUM, XANAX, opioids, alcohol, sleep medicines, sedating antihistamines or other CNS depressants may add sedation and respiratory depression; older adults also require priority review of confusion, impaired coordination and falls. Continued use can produce physical dependence, and abrupt stopping or rapid reduction can cause life-threatening reactions including seizures. A shared class or milligram figure does not permit one-for-one self-conversion, combination or rotation. VALIUM is the U.S. regulatory dossier for diazepam C-IV oral tablets. The 2/5/10 mg figures are amounts per tablet, 100 Tablets is the bottle count, and a score or V-shaped perforation does not create permission to split or taper. Opioids, alcohol or other CNS depressants can add profound sedation and respiratory depression. Older adults also require priority review of accumulation, somnolence, ataxia, falls and fractures. Continued use can produce physical dependence, and abrupt stopping or rapid reduction can be life-threatening. Do not self-stop, copy a taper, or convert, combine or rotate VALIUM one-for-one with XANAX or another benzodiazepine from a shared class or milligram figure. DILANTIN is the U.S. brand dossier for extended phenytoin sodium capsules. The 30/100 mg figures are amounts per capsule and 100 Capsules is the bottle count. Phenytoin metabolism is saturable and nonlinear, so small dose or interaction changes can produce disproportionate concentration changes. Do not abruptly stop, self-switch brand or form, assemble a capsule count, combine or rotate from a shared ingredient or milligram figure. Older adults, people using several medicines, and those with renal/hepatic impairment or abnormal albumin especially require professional review of the exact pack, complete medicine list and phenytoin levels. MIRAPEX immediate-release tablets and MIRAPEX ER extended-release tablets are distinct pramipexole release products and must not be self-converted, assembled, split or substituted from a shared ingredient or total milligrams. Older adults and people using several medicines require priority review of sudden sleep, somnolence, orthostatic hypotension, hallucinations, impulse-control problems, gait/falls, kidney function and withdrawal. If levodopa or another dopaminergic medicine appears on the same list, do not self-combine, separate, reduce or abruptly stop it. LITHOBID is the U.S. brand dossier for 300 mg extended-release lithium carbonate oral tablets; 300 mg is the labelled amount per tablet and 100 tablets is the package count, neither an individual's tablet count or schedule. An extended-release tablet, an immediate-release lithium carbonate tablet and lithium citrate oral liquid cannot be self-converted, combined or substituted from the word “lithium” or a milligram figure. Serum lithium, kidney function, thyroid, calcium, the complete medicine list, and diuretics, ACE inhibitors/ARBs, NSAID pain medicines, dehydration, vomiting or diarrhoea require professional review; do not self-catch-up, reduce, stop or separate times. Marked tremor, unsteadiness, slurred speech, severe drowsiness or confusion, persistent vomiting/diarrhoea, fainting, abnormal heartbeat, breathing difficulty or inability to remain safe requires local emergency or medical support immediately with every medicine pack. These medicines especially should not be abruptly self-stopped, increased, changed, alternated or shared because of a change in sleep, mood, pain, sensation or behaviour. CELEXA is citalopram and LEXAPRO is escitalopram; a shared SSRI class, related name or milligram figure does not permit self-conversion, combination or rotation. CELEXA's reference to CYP2C19 poor metabolisers does not mean everyone needs whole-genome screening. DESYREL is the historical trazodone brand archive, while the exact current packs come from a generic label; the labelled indication is not a webpage sleep prescription. Somnolence, unsteadiness, falls, hyponatraemia, QT and serotonergic risks must be reviewed with age, the full medicine list and actual pack, not used to self-start, combine, stop or switch because someone wants sleep. Regular tablets, delayed-release tablets, extended-release tablets, capsules, orally disintegrating tablets and oral liquids require exact-product checking. Shared ingredients, a similar purpose or a potential for drowsiness do not permit self-co-use or substitution. SEROQUEL immediate-release tablets and SEROQUEL XR have different release characteristics; XR must be swallowed whole and must not be split, chewed or crushed, and a matching milligram figure does not permit self-interchange. DEPAKOTE is a divalproex sodium delayed-release tablet that must be swallowed whole; DEPAKOTE ER and Sprinkle are different dosage forms, and a shared mg strength does not permit one-for-one self-substitution. DAYVIGO (lemborexant), BELSOMRA (suvorexant), LUNESTA (eszopiclone) and AMBIEN (zolpidem) are different medicines. LUNESTA 1, 2 and 3 mg are amounts per tablet, while 30 Tablets is the bottle count. Its boxed warning for complex sleep behaviours, next-day impairment, additive effects with alcohol, opioids or other sedatives, and fall risk in older adults require priority review. Even though the first two are dual orexin-receptor antagonists, they cannot be converted, combined or rotated by milligrams. Marked next-day somnolence, reduced food or fluid intake, unsteadiness on standing, a fall, or gait or awareness changes in an older adult requires avoiding driving and timely review of the full medicine list, alcohol and other CNS depressants, not abrupt self-withdrawal. SINEMET is an immediate-release carbidopa/levodopa tablet. RYTARY and CREXONT are distinct capsules with different strengths and extended-release designs. STALEVO additionally contains entacapone. For swallowing difficulty, current RYTARY and CREXONT labels both permit sprinkling the complete contents of one whole capsule on applesauce and consuming immediately, but that does not make the products the same. The four products cannot be self-converted, combined or substituted from shared ingredients or milligrams. Have a pharmacist or clinician review every pack, prescriptions, OTC products, alcohol use and the complete medicine list together.

PLAN B ONE-STEP is the U.S. OTC dossier for a single levonorgestrel 1.5 mg emergency-contraception tablet. The 1.5 mg figure is the amount per tablet, and retail NDC 69536-162-88 has one blister with one tablet; clinic-only, non-retail NDC 69536-146-19 is excluded from the retail panel. The cited U.S. Drug Facts says to use as soon as possible within 72 hours after unprotected sex or contraceptive failure and to contact a professional if vomiting occurs within two hours. This is not a cross-market or individual plan, regular birth control or STI protection. Efavirenz, rifampin or certain seizure medicines may reduce effectiveness, so the full medicine list requires review. A matching 1.5 mg amount or shared ingredient does not prove automatic substitution of another OTC product. YAZ is the U.S. dossier for drospirenone/ethinyl estradiol combination oral tablets. Each blister has 24 light-pink active tablets, each containing drospirenone 3 mg and ethinyl estradiol 0.02 mg, plus 4 white inert tablets; NDC 50419-405-03 has three blisters. The two mg figures are ingredients in one active tablet, while 24, 4, 28 and 3 are packaging layers, not an individual schedule. Women over 35 who smoke should not use YAZ; thrombotic, potassium and interaction risks require review against the current label and complete medicine list. YASMIN, BEYAZ, SAFYRAL, SLYND and other 21+7 or 24+4 products must not be self-substituted, assembled or alternated. Missed or wrong tablets, switching or stopping require the exact current official label and a clinician or pharmacist; the site does not generate an individual regimen.

This group first helps prevent once weekly from being read as once daily. The site does not generate an individual schedule; if methotrexate was taken extra, on consecutive days, or there is uncertainty, contact local emergency, poison-information or treating services immediately and take the pack and prescription.